Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 1 | Journal of Otolaryngology - Head & Neck Surgery

Fig. 1

From: The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

Fig. 1

Significant improvements in TPS, SNOT-22 and smell identification are seen after 6 months of dupilumab in both InitialTPS ≤ 4 and InitialTPS ≥ 5 groups. Box plots indicating median total polyp score (TPS) (y-axis = score 0–8) (a), Sniffin’ Sticks 16 scores (y-axis = score 0–16) (b) and total Sino Nasal Outcome Test 22 score (SNOT-22) (y-axis = score 0–110) (c) at baseline and after 6 months of dupilumab therapy (x-axes). Thick lines within the box plots indicate the median, the edges indicate the lower and upper quartiles and the whiskers indicate variability outside the upper and lower quartiles. Single dots represent outliers. Significant differences are indicated by stars (**: P ≤ 0.01, ***: P ≤ 0.001)

Back to article page